About
Kulkarni received a Ph.D. in bioengineering and nanotechnology from the University of Washington and a B.Tech. from the Indian Institute of Technology, according to the proxy statement. Before CRISPR he was at McKinsey & Company from 2006 to 2015, and his most recent title there was partner in the pharmaceuticals and biotechnology practice. Other pharmaceutical leaders with pages on Whoo include Reshma Kewalramani of Vertex Pharmaceuticals and Yvonne Greenstreet of Alnylam.
Whoo compiled this page from public sources: CRISPR Therapeutics third-quarter 2026 results release (via Finviz), CRISPR Therapeutics 2026 proxy statement (SEC), Aspen Ideas. It is not affiliated with or endorsed by Samarth Kulkarni. Are you Samarth Kulkarni? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.
Want a page like this? Create yours from your résumé.
Experience
Chairman and Chief Executive Officer — CRISPR Therapeutics
December 2017 – Present
- Board member since June 2018
- Chairman since September 2023
- Held various titles; partner was the most recent
President and Chief Business Officer — CRISPR Therapeutics
Partner, Pharmaceuticals and Biotechnology practice — McKinsey & Company
2006 – 2015